Spots Global Cancer Trial Database for bortezomib (velcade)
Every month we try and update this database with for bortezomib (velcade) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis | NCT01383759 | Light Chain Dep... Light Chain and... Monoclonal Immu... Amyloidosis | Bortezomib/Dexa... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma | NCT01830465 | Non Hodgkin's F... | Bortezomib (VEL... Rituximab | 18 Years - 90 Years | Gruppo Italiano Studio Linfomi | |
| Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | NCT00142129 | Waldenstrom's M... Lymphoplasmacyt... | Bortezomib (Vel... | 18 Years - 90 Years | Dana-Farber Cancer Institute | |
| Panobinostat/Velcade in Multiple Myeloma | NCT00891033 | Multiple Myelom... | Bortezomib (Vel... Panobinostat | 18 Years - | University of Arkansas | |
| Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | NCT00142129 | Waldenstrom's M... Lymphoplasmacyt... | Bortezomib (Vel... | 18 Years - 90 Years | Dana-Farber Cancer Institute | |
| Velcade in MALT Lymphoma Patients | NCT00373906 | MALT Lymphoma | Bortezomib (Vel... | 18 Years - | Medical University of Vienna | |
| Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis | NCT01383759 | Light Chain Dep... Light Chain and... Monoclonal Immu... Amyloidosis | Bortezomib/Dexa... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Panobinostat/Velcade in Multiple Myeloma | NCT00891033 | Multiple Myelom... | Bortezomib (Vel... Panobinostat | 18 Years - | University of Arkansas | |
| Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy | NCT00972959 | Multiple Myelom... | Bortezomib Zoledronic Acid Dexamethasone | 18 Years - | University of Athens | |
| Velcade in MALT Lymphoma Patients | NCT00373906 | MALT Lymphoma | Bortezomib (Vel... | 18 Years - | Medical University of Vienna | |
| Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation | NCT00369226 | Hematologic Mal... | Bortezomib (Vel... Tacrolimus Methotrexate blood stem cell... | 18 Years - | Dana-Farber Cancer Institute | |
| Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | NCT00142129 | Waldenstrom's M... Lymphoplasmacyt... | Bortezomib (Vel... | 18 Years - 90 Years | Dana-Farber Cancer Institute | |
| Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy | NCT00972959 | Multiple Myelom... | Bortezomib Zoledronic Acid Dexamethasone | 18 Years - | University of Athens | |
| Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | NCT01062230 | Multiple Myelom... | Bortezomib (Vel... | 18 Years - | University of Arkansas |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
